Doxycycline, Indian WHO-GMP supply for rickettsial and tick-borne illness, malaria prophylaxis, cholera response and Lyme.

The high-volume line is the 100 mg capsule and tablet (doxycycline hyclate or monohydrate), the standard treatment strength across respiratory, rickettsial, Lyme, malaria-prophylaxis and chlamydial use. We also source the 50 mg strength, delayed-release tablets (75, 100 and 150 mg) for patients prone to gastrointestinal upset, and the low-dose sub-antimicrobial products: 40 mg modified-release (30 mg immediate plus 10 mg delayed release) for rosacea, and 20 mg for adjunctive periodontitis. An intravenous doxycycline hyclate formulation is available for patients who cannot take oral therapy. Tell us the salt (hyclate or monohydrate), strength, pack and blister preference and we route to the matching WHO-GMP line.

We do not claim WHO Prequalification for doxycycline. WHO PQ scope centres on priority-disease medicines, and doxycycline is not something we assert a PQ listing for without checking the live WHO PQ list for a given product. What we do provide for institutional and donor tenders is the standard, defensible pack: a WHO-GMP certificate and a product-specific Certificate of Pharmaceutical Product (CoPP) in WHO format from CDSCO or the State FDA (applications now route through CDSCO's ONDLS digital portal; a CoPP is valid for two years), plus stringent-regulatory-authority approvals where the manufacturer holds them. Doxycycline is a WHO Essential Medicines List item in the AWaRe Access group, which we document for antimicrobial-stewardship review.

The UK (NHS hospital and primary-care supply, or the MHRA Specials / named-patient route during shortage), the GCC (UAE via the EDE, Saudi Arabia via the SFDA, and Kuwait, Oman, Qatar and Bahrain) through licensed local importers, and sub-Saharan Africa (Nigeria, Kenya, Ghana, South Africa, Ethiopia, Tanzania, Uganda, Rwanda) for public-sector tenders and teaching-hospital supply. Two demand patterns are specific to doxycycline: malaria chemoprophylaxis for travellers, military and institutional buyers heading into chloroquine-resistant regions, and cholera outbreak response, where it is a recommended option alongside rehydration. Germany (under section 72 AMG), France, Brazil (ANVISA), Mexico (COFEPRIS) and the Philippines through licensed importers. We do not supply into India. Full coverage is at markets.

The WHO AWaRe framework sorts antibiotics by stewardship priority. Doxycycline sits in the Access group, the tier for agents recommended as first- or second-choice empiric treatment for common infections, with a comparatively lower resistance risk and an expectation of wide availability. Azithromycin, by contrast, is in the Watch group. For a formulary or tender committee this matters: Access antibiotics are the ones stewardship programmes want available and used first, so a well-documented Access-group generic like doxycycline is often the preferred procurement choice where it is clinically appropriate.

Carefully, because the picture has changed. Under traditional labelling, tetracyclines as a class have been avoided in pregnancy (particularly the second and third trimesters) and in children under 8 because of an association with permanent tooth discoloration and enamel hypoplasia. More recent evidence refines this: doxycycline binds calcium less avidly than older tetracyclines, and a systematic review together with CDC and AAP guidance indicate that short courses (studied mainly at 10 days or less) in under-8s do not cause visible tooth staining, so CDC and AAP now recommend doxycycline as first-line for Rocky Mountain spotted fever and other rickettsial illness in children of any age. First-trimester exposure data have not shown a clear increase in congenital anomalies, though pregnancy use remains an individualised clinical decision. Our destination-language pack inserts carry both the traditional caution and this newer nuance; any use in pregnancy or young children should be guided by a clinician.

Two counselling points sit on every pack insert we ship. First, pill oesophagitis and ulceration can occur, so doxycycline should be taken with a full glass of water and the patient should stay upright (sitting or standing) for at least 30 minutes after each dose. Second, photosensitivity, an exaggerated sunburn reaction, is a well-recognised effect that can be relatively common on longer courses such as malaria prophylaxis, so sun protection is advised. Absorption is also reduced by divalent and trivalent cations, so antacids, calcium, iron and magnesium supplements and dairy should be separated in time from each dose. These are labelling and counselling responsibilities we carry on the supply side; the prescribing decision stays with the clinician.

Yes. Full CTD Module 3 dossiers are available against a non-disclosure agreement for registration with the MHRA, the GCC regulators (EDE, SFDA and the GCC central route), NAFDAC, PPB, SAHPRA, EFDA, TMDA, NDA, BfArM, ANSM, ANVISA, COFEPRIS, FDA Philippines and comparable bodies. Doxycycline capsules and tablets are stored at USP Controlled Room Temperature (20-25C, with excursions permitted 15-30C), protected from light and moisture in a tight, light-resistant container; typical shelf life is around 24 to 36 months depending on the manufacturer and formulation (refer to the specific product label and CoA for the labelled shelf life). For hot and humid destinations we confirm climatic-zone-appropriate stability data (Zone IVa at 30C/65% RH, Zone IVb at 30C/75% RH, per WHO stability guidance derived from the ICH Q1F climatic-zone scheme) and specify Alu-Alu blister or HDPE-with-desiccant packaging.

We can supply the 100 mg and 200 mg doxycycline that DoxyPEP programmes use, but it is worth being precise about what DoxyPEP is. In 2024 the US CDC issued clinical guidelines (MMWR, 6 June 2024) suggesting doxycycline post-exposure prophylaxis, a single 200 mg dose within 72 hours after sex, not exceeding 200 mg per 24 hours, for gay and bisexual men and transgender women who have had a bacterial STI in the preceding 12 months, as part of a comprehensive sexual-health approach. In clinical trials it reduced chlamydia and syphilis by roughly 70% or more; its effect on gonorrhoea was smaller and inconsistent, and tetracycline-resistant gonorrhoea can blunt that benefit, so it is not relied on for gonorrhoea prevention. This is an off-label CDC clinical recommendation for a defined group, not an approved indication, and we label it as such.